Gender effects of the COMT Val(158)Met genotype on verbal fluency in healthy adults

Imagem de Miniatura
Arquivos
art_SOEIRO-DE-SOUZA_Gender_effects_of_the_COMT_Val(158)Met_genotype_on_2013.PDF (453.08 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
LIMA, Bruno
FERNANDES, Fernando
Citação
MOLECULAR MEDICINE REPORTS, v.8, n.3, p.837-844, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cognitive performance in healthy individuals is associated with gender differences in specific tests; a female advantage has been demonstrated in language tests, whereas a male advantage has been demonstrated in spatial relation examinations. The prefrontal cortex (PFC) mediates important cognitive domains and is influenced by dopamine (DA) activity. The single nucleotide polymorphism (SNP) rs4680 in the catechol-O-methyltransferase (COMT) gene results in an amino acid substitution from valine (Val) to methionine (Met). The Met allele has been demonstrated to decrease COMT enzyme activity and improve PFC cognitive function. COMT regulates DA activity in the PFC and exhibits gender effects. The aim of the present study was to investigate the gender-specific effects of the COMT genotype on cognition in healthy young adults. Seventy-six healthy subjects were genotyped for COMT rs4680 and submitted to an extensive range of neuropsychological tests assessing aspects of PFC function. The COMT Met allele influenced the performance of executive function. The results revealed gender effects of the COMT rs4680 Met allele on verbal fluency, with positive effects in males and negative effects in females. This suggested that DA activity affects cognitive function in different ways, according to gender.
Palavras-chave
dopamine, gender, cognition
URI
https://observatorio.fm.usp.br/handle/OPI/4553
Referências
  1. Andrewes D, 2001, NEUROPSYCHOLOGY THEO
  2. Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.bps.2004.08.019
  3. Barnett JH, 2007, AM J PSYCHIAT, V164, P142, DOI 10.1176/appi.ajp.164.1.142
  4. Barnett JH, 2008, BIOL PSYCHIAT, V64, P137, DOI 10.1016/j.biopsych.2008.01.005
  5. Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542
  6. BOLLA KI, 1990, J CLIN PSYCHOL, V46, P623, DOI 10.1002/1097-4679(199009)46:5<623::AID-JCLP2270460513>3.0.CO;2-C
  7. BOUDIKOVA B, 1990, CLIN PHARMACOL THER, V48, P381
  8. Bray NJ, 2003, AM J HUM GENET, V73, P152, DOI 10.1086/376578
  9. Bruder GE, 2005, BIOL PSYCHIAT, V58, P901, DOI 10.1016/j.biopsych.2005.05.010
  10. Caldu X, 2007, NEUROIMAGE, V37, P1437, DOI 10.1016/j.neuroimage.2007.06.021
  11. Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589
  12. Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7
  13. COHN CK, 1971, LIFE SCI, V10, P1351, DOI 10.1016/0024-3205(71)90335-3
  14. Colzato LS, 2010, NEUROSCIENCE, V167, P709, DOI 10.1016/j.neuroscience.2010.02.029
  15. Cousins DA, 2009, BIPOLAR DISORD, V11, P787, DOI 10.1111/j.1399-5618.2009.00760.x
  16. Darby D., 2005, WALSHS NEUROPSYCHOLO
  17. de Frias CM, 2004, BEHAV GENET, V34, P533, DOI 10.1023/B:BEGE.0000038491.06972.8c
  18. de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018
  19. Dempster EL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-10
  20. Dennis NA, 2010, CEREB CORTEX, V20, P672, DOI 10.1093/cercor/bhp132
  21. Devinsky O, 2004, NEUROLOGY COGNITIVE
  22. De Vries GJ, 2004, ENDOCRINOLOGY, V145, P1063, DOI 10.1210/en.2003-1504
  23. Diamond A, 2004, AM J PSYCHIAT, V161, P125, DOI 10.1176/appi.ajp.161.1.125
  24. Do Prado CM, 2012, BIPOLAR DISORD, V14, P554
  25. Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598
  26. FAHNDRICH E, 1980, ACTA PSYCHIAT SCAND, V61, P427
  27. FITZGERALD GA, 1980, CLIN SCI, V58, P423
  28. FLODERUS Y, 1981, CLIN GENET, V19, P392
  29. Gasbarri A, 2008, PSYCHONEUROENDOCRINO, V33, P964, DOI 10.1016/j.psyneuen.2008.04.007
  30. Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991
  31. Goldman-Rakic PS, 2004, PSYCHOPHARMACOLOGY, V174, P3, DOI 10.1007/s00213-004-1793-y
  32. Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490
  33. Granon S, 2000, J NEUROSCI, V20, P1208
  34. Halari R, 2005, BEHAV NEUROSCI, V119, P104, DOI 10.1037/0735-7044.119.1.104
  35. Halbreich U, 1997, NEUROLOGY, V48, pS16
  36. Harrison PJ, 2008, NEUROPSYCHOPHARMACOL, V33, P3037, DOI 10.1038/sj.npp.1301543
  37. Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1166, DOI 10.1016/j.neuropsychologia.2005.10.006
  38. Herlitz A, 1997, MEM COGNITION, V25, P801, DOI 10.3758/BF03211324
  39. Jiang H, 2003, NEUROPHARMACOLOGY, V45, P1011, DOI 10.1016/S0028-3908(03)00286-7
  40. Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662
  41. Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032
  42. Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007
  43. LAITINEN J, 1994, BIOTECHNIQUES, V17, P316
  44. Lezak MD, 2004, NEUROPSYCHOLOGICAL A
  45. Libon D, 1994, NEUROPSYCHOLOGY, V8, P38, DOI 10.1037/0894-4105.8.1.38
  46. Lindamer LA, 1997, PSYCHOPHARMACOL BULL, V33, P221
  47. Mattay VS, 2003, P NATL ACAD SCI USA, V100, P6186, DOI 10.1073/pnas.0931309100
  48. Mehta MA, 2000, J NEUROSCI, V20
  49. Meyer-Lindenberg A, 2006, MOL PSYCHIATR, V11, P867, DOI 10.1038/sj.mp.4001860
  50. Miller BL, 2007, HUMAN FRONTAL LOBES
  51. Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585
  52. O'Hara R, 2006, NEUROSCI LETT, V409, P205, DOI 10.1016/j.neulet.2006.09.047
  53. PHILIPPU G, 1981, PSYCHIAT RES, V4, P139, DOI 10.1016/0165-1781(81)90017-2
  54. Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X
  55. RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2
  56. SELNES OA, 1991, PERCEPT MOTOR SKILL, V73, P539, DOI 10.2466/PMS.73.5.539-550
  57. Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22
  58. Solis-Ortiz S, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-67
  59. SPRAGUE RL, 1977, SCIENCE, V198, P1274, DOI 10.1126/science.337493
  60. Strauss E., 2006, COMPENDIUM NEUROPSYC
  61. Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4
  62. Tunbridge E, 2004, SYNAPSE, V51, P112, DOI 10.1002/syn.10286
  63. Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024
  64. Tunbridge EM, 2007, AM J MED GENET B, V144B, P834, DOI 10.1002/ajmg.b.30539
  65. van Exel E, 2001, J NEUROL NEUROSUR PS, V71, P29, DOI 10.1136/jnnp.71.1.29
  66. van Hooren SAH, 2007, AGING NEUROPSYCHOL C, V14, P40, DOI 10.1080/138255890969483
  67. Wayment HK, 2001, J NEUROSCI, V21, P35
  68. Wechsler D, 1999, WECHSLER ABBREVIATED
  69. Wechsler D., 1981, WECHSLER ADULT INTEL
  70. Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19
  71. Zahrt J, 1997, J NEUROSCI, V17, P8528

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - LIM/27